Phase 1 × Completed × Bendamustine Hydrochloride × Clear all A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Completed
130 enrolled
FT576 in Subjects With Multiple Myeloma
Phase 1 Completed
31 enrolled
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Phase 1 Completed
20 enrolled
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Phase 1 Completed
26 enrolled
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase 1 Completed
50 enrolled
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Phase 1 Completed
18 enrolled 10 charts
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1 Completed
16 enrolled
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Phase 1 Completed
18 enrolled
BRiM
Phase 1 Completed
11 enrolled 20 charts
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Completed
60 enrolled
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
9 enrolled
A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
Phase 1 Completed
81 enrolled
SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
Phase 1 Completed
18 enrolled
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Completed
10 enrolled
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
241 enrolled 31 charts
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Completed
18 enrolled
A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
9 enrolled
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Phase 1 Completed
84 enrolled
BRP
Phase 1 Completed
33 enrolled 13 charts
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Phase 1 Completed
160 enrolled
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Phase 1 Completed
26 enrolled
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
Phase 1 Completed
60 enrolled
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Completed
20 enrolled
Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
Phase 1 Completed
18 enrolled
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
Phase 1 Completed
8 enrolled
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
30 enrolled
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Phase 1 Completed
34 enrolled
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
Phase 1 Completed
8 enrolled
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
Phase 1 Completed
29 enrolled
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Phase 1 Completed
12 enrolled 15 charts
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Completed
16 enrolled
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Phase 1 Completed
4 enrolled
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
Phase 1 Completed
41 enrolled 12 charts
GAUDI
Phase 1 Completed
137 enrolled
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
Phase 1 Completed
48 enrolled
Bendamustine and Bevacizumab for Advanced Cancers
Phase 1 Completed
59 enrolled
Phase I BLR
Phase 1 Completed
28 enrolled
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 1 Completed
32 enrolled
Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy
Phase 1 Completed
6 enrolled
RiTa
Phase 1 Completed
38 enrolled